AFLAC INC — Form 8-K
Filed November 4, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 42/100
What the filing says
Aflac reported Q3 2026 adjusted EPS of $2.43 (−2.4% YoY), or $2.46 excluding FX (−1.2%). Net EPS plummeted 80.2% to $0.61 due to $1.1B investment losses from strategic portfolio repositioning. Aflac Japan ceded ¥500B (~$3.1B) cancer reserves to Aflac Re Bermuda, expected to release ~$1B capital. Company raised 2026 Japan profit margin guidance to 35%–38% (from prior range). Share repurchases: $804M; dividends: $305M in Q3. Fourth quarter dividend raised to $0.61/share (44 consecutive years of increases). Leverage: 22.6% (within 20%–25% target); regulatory ESR: 225% (or 238% with USP); combined RBC: ~575%.
Why this rating
Portfolio repositioning losses ($1.1B) are non-recurring. Underlying adjusted earnings down 8.5%, but actuarial unlocks and reinsurance strategy boost core profitability. Japan margin guidance raised; U.S. solid. Capital deployment ($1.1B) strong relative to $56B market cap (2% of value). No going-concern risk; ordinary quarterly earnings management.
See more from November 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.